Alnylam Pharmaceuticals | ALNY - Vertriebs- Und Verwaltungskosten

Aktienkurs
321.18
Täglich Wechseln
-6.07 -1.85%
Monatlich
-0.37%
Jährlich
41.94%
Q2 Prognose
309.25




Vertriebs- Und Verwaltungskosten Veränderung Datum
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amgen USD 1.94B 237M 2025-12
Arrowhead Research USD 46.02M 8.84M 2025-12
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Incyte USD 390.41M 61.33M 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
Moderna USD 308M 40M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Novartis USD 3.44B 132M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.75B 455M 2025-12
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Takeda JPY 282.78B 29.23B 2025-12
Tectonic Therapeutic USD 3.44M 1.52M 2025-12
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12
Xencor USD 17.04M 70.74M 2025-12